D18S880 microsatellite polymorphism of carnosinase gene and diabetic nephropathy: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 4, 2013, Pages 289-294

  Zhu, Ji Min ^a,b   Wang, Bin ^a   Li, Jing ^b   Chen, Gui Mei ^a   Fan, Yin Guang ^a   Feng, Chen Chen ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLHISTIDINE DIPEPTIDASE; ENZYME; LEUCINE; TRINUCLEOTIDE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CAUCASIAN; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROSATELLITE POLYMORPHISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE REPEATS; POLYMORPHISM, GENETIC;

EID: 84875650637     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0341     Document Type: Article

References (32)

1. Ahluwalia TS, Lindholm E, Groop LC (2011) Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54:2295-2302.
2. Alkhalaf A, Bakker SJ, Bilo HJ, et al. (2010) A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia 53:2562-2568.
3. Boldyrev A, Bulygina E, Leinsoo T, et al. (2004) Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp Biochem Physiol B Biochem Mol Biol 137:81-88.
4. Bowden DW, Colicigno CJ, Langefeld CD, et al. (2004) A genome scan for diabetic nephropathy in African Americans. Kidney Int 66:1517-1526.
5. Chandie Shaw PK, Baboe F, van Es LA, et al. (2006) South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 29:1383-1385.
6. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129.
7. Craig DW, Millis MP, DiStefano JK (2009) Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to Type 1 diabetes. Diabet Med 26:1090-1098.
8. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
9. Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634.
10. Freedman BI, Hicks PJ, Sale MM, et al. (2007) A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic endstage renal disease in European Americans. Nephrol Dial Transplant 22:1131-1135.
11. Freedman BI, Tuttle AB, Spray BJ (1995) Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25:710-713.
12. Gonzalez AM, Maceira BM, Perez E, et al. (2012) Genetics, environment, and diabetes-related end-stage renal disease in the Canary Islands. Genet Test Mol Biomarkers 16:859-864.
13. Guilbert JJ (2006) The World Health Report 2006: working together for health. Educ Health (Abingdon) 19:385-387.
14. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
15. Hipkiss AR (1998) Carnosine, a protective, anti-ageing peptide? Int J Biochem Cell Biol 30:863-868.
16. Hipkiss AR, Brownson C, Bertani MF, et al. (2002) Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci 959:285-294.
17. Hou WC, Chen HJ, Lin YH (2003) Antioxidant peptides with Angiotensin converting enzyme inhibitory activities and applications for Angiotensin converting enzyme purification. J Agric Food Chem 51:1706-1709.
18. Janssen B, Hohenadel D, Brinkkoetter P, et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54:2320-2327.
19. Lin CC, Wu CT, Wu LS (2011) Ectonucleotide pyrophosphatase/ phosphodiesterase 1 K173Q polymorphism is associated with diabetic nephropathy in the Taiwanese population. Genet Test Mol Biomarkers 15:239-242.
20. Mantel N, Haenszel W(1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
21. Masson E, Troncy L, Ruggiero D, et al. (2005) a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy? Diabetes 54:220- 227.
22. McDonough CW, Hicks PJ, Lu L, et al. (2009) The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet 126:265-275.
23. Mooyaart AL, Zutinic A, Bakker SJ, et al. (2010) Association between CNDP1 genotype and diabetic nephropathy is sex specific. Diabetes 59:1555-1559.
24. Movva S, Alluri RV, Venkatasubramanian S, et al. (2011) Association of methylene tetrahydrofolate reductase C677T genotype with type 2 diabetes mellitus patients with and without renal complications. Genet Test Mol Biomarkers 15:257-261.
25. Pei D, Huang YJ, Hsieh CH, et al. (2010) The genetic background difference between diabetic patients with and without nephropathy in a Taiwanese population by linkage disequilibrium mapping using 382 autosomal STR markers. Genet Test Mol Biomarkers 14:433-438.
26. Quinn M, Angelico MC, Warram JH, et al. (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945.
27. Riedl E, Koeppel H, Brinkkoetter P, et al. (2007) A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes 56:2410-2413.
28. Seaquist ER, Goetz FC, Rich S, et al. (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165.
29. Shoukry A, Shalaby SM, Abdelazim S, et al. (2012) Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet Test Mol Biomarkers 16:574-579.
30. Vardarli I, Baier LJ, Hanson RL, et al. (2002) Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 62:2176-2183.
31. Wanic K, Placha G, Dunn J, et al. (2008) Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 57:2547-2551.
32. Yu R, Bo H, Huang S (2012) Association between the PPARG gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. Genet Test Mol Biomarkers 16:429-434.